PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer

NCT04176952 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped Due to funding being withdrawn

Conditions

Neoplasms Pancreatic

Interventions

DRUG: FOLFOX-A
DRUG: AG

Sponsor

Judith Dixon-Hughes

Collaborators

[object Object]
[object Object]